Listing 12.02 in 2026: Neurocognitive Disorder SSDI Claims for Alzheimer, Vascular Dementia, TBI, and Parkinson Cognitive Disorder

By Anthony Albert, Benefits Research Director, Disability Exchange. Published June 26, 2026. Disability Exchange is privately owned and not affiliated with the SSA.

If you filed an SSDI or SSI claim because Alzheimer disease, vascular dementia, frontotemporal dementia, Lewy body dementia, Parkinson disease with cognitive impairment, traumatic brain injury sequelae, or HIV associated neurocognitive disorder took away your ability to hold a job, Social Security evaluates you under Listing 12.02 of the Blue Book. The text of the listing hasn't changed since the January 2017 mental disorders revision, but the way examiners read it has tightened. Neurocognitive claims are decided on neuropsychological testing, medical imaging, and longitudinal treatment notes. Subjective complaints of memory loss without objective deficits on standardized testing almost never win at Step 3.

This page walks Listing 12.02 line by line. Paragraph A six cognitive domains. Paragraph B four areas of mental functioning with the SSA 5-point severity scale. Paragraph C two-year serious and persistent path with marginal adjustment. Then it covers the neuropsychological battery SSA expects, the imaging that supports the diagnosis, the medication list that proves the disorder is being treated, and two worked Massachusetts and Florida cases.

The Listing 12.02 Text Read Word by Word

Listing 12.02 reads: neurocognitive disorders (see 12.00B1), satisfied by A and B, or A and C. You can win on Paragraph A plus Paragraph B, or on Paragraph A plus Paragraph C. You cannot win on B alone or C alone. Paragraph A is the medical foundation. Without it, neither B nor C gets you to a Step 3 allowance.

Section 12.00B1 of the preamble tells you what category of disorder fits this listing. The verbatim text reads: "These disorders are characterized by a clinically significant decline in cognitive functioning. Symptoms and signs may include, but are not limited to, disturbances in memory, executive functioning (that is, higher-level cognitive processes; for example, regulating attention, planning, inhibiting responses, decision-making), visual-spatial functioning, language and speech, perception, insight, judgment, and insensitivity to social standards." That last item, insensitivity to social standards, is the SSA hook for frontotemporal dementia behavioral variant claims.

Section 12.00B1 lists specific examples. Major neurocognitive disorder. Dementia of the Alzheimer type. Vascular dementia. Dementia due to a medical condition such as a metabolic disease (for example, late-onset Tay-Sachs disease), HIV infection, vascular malformation, progressive brain tumor, neurological disease such as multiple sclerosis, Parkinsonian syndrome, or Huntington disease, or traumatic brain injury. Substance-induced cognitive disorder associated with drugs of abuse, medications, or toxins. The preamble also tells you what does not belong here. Intellectual disorder routes through 12.05. Autism spectrum disorder routes through 12.10. ADHD and other neurodevelopmental disorders route through 12.11. So an adult ADHD claim is not a 12.02 claim no matter how severe the attention deficit.

One more routing rule matters. The preamble points to Section 11.00G. Cognitive impairments that result from neurological disorders get evaluated under the body system listing first. So a multiple sclerosis claimant with cognitive decline gets evaluated under Listing 11.09 first. If 11.09 isn't met, then 12.02 is the fallback. A Parkinson claimant with cognitive decline gets evaluated under Listing 11.06 first. Same fallback rule. The practical effect: the medical record needs to show both the neurological diagnosis and the cognitive deficit, because the adjudicator may decide the file either way.

Paragraph A: The Six Cognitive Domains

Paragraph A1 requires medical documentation of a significant cognitive decline from a prior level of functioning in one or more of six cognitive domains. The list reads exactly as the DSM-5-TR Criterion A for major neurocognitive disorder. Complex attention. Executive function. Learning and memory. Language. Perceptual-motor. Social cognition. SSA borrowed the DSM-5 wording verbatim. So the chart should track these six domain names.

Complex attention covers sustained attention, divided attention, selective attention, and processing speed. A typical deficit shows on Trail Making Test Part A and Symbol Digit Modalities Test. Executive function covers planning, decision-making, working memory, response to feedback, inhibition, and mental flexibility. Standard tests include Trail Making Test Part B, Stroop, Wisconsin Card Sorting Test, and Frontal Assessment Battery. Learning and memory covers immediate memory, recent memory, and recent autobiographical memory. Standard tests include Wechsler Memory Scale Fourth Edition (WMS-IV), Hopkins Verbal Learning Test Revised (HVLT-R), Brief Visuospatial Memory Test Revised (BVMT-R), and the Logical Memory and Verbal Paired Associates subtests.

Language covers expressive language including naming, word finding, fluency, grammar, syntax, and receptive language. Standard tests include Boston Naming Test, semantic and phonemic fluency tasks, and Token Test. Perceptual-motor covers visual perception, visuoconstructional, perceptual-motor, praxis, and gnosis. Standard tests include Rey Complex Figure copy and recall, Block Design from WAIS-IV, and Judgment of Line Orientation. Social cognition covers recognition of emotions, theory of mind. This is the domain that drives behavioral variant frontotemporal dementia claims. Standard tests include Reading the Mind in the Eyes Test and Faux Pas Recognition Test.

The word "significant" in Paragraph A1 matters. DSM-5-TR defines significant decline as performance two or more standard deviations below appropriate norms, generally below the third percentile. SSA does not bind itself to that exact threshold, but examiners read neuropsychological reports looking for it. A claimant with WMS-IV Delayed Memory Index of 65 (98th percentile below the mean, more than 2 SD below norms) clearly satisfies Paragraph A. A claimant whose only documentation is a Mini-Mental State Examination of 26 with no domain-specific testing is in trouble.

Bedside Cognitive Screens Versus Full Neuropsychological Testing

Bedside screens are not enough at Step 3. The Mini-Mental State Examination (MMSE) ranges from 0 to 30. A score below 24 is generally accepted as cognitive impairment. Below 18 is moderate dementia. Below 10 is severe. The Montreal Cognitive Assessment (MoCA) ranges from 0 to 30. A score below 26 is generally accepted as mild cognitive impairment or worse. The Saint Louis University Mental Status (SLUMS) and Mini-Cog are also common.

The trap with bedside screens is they don't measure individual cognitive domains in enough depth to satisfy Paragraph A's six-domain language. A claimant with an MMSE of 22 is impaired, but the adjudicator can't tell which domains are hit hardest. The strongest 12.02 files include both bedside screens and a full neuropsychological battery. A claimant with MMSE 22, MoCA 19, and a Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score of 68 with Immediate Memory Index of 55 and Delayed Memory Index of 52 has every domain mapped. That file wins.

The neuropsychological battery that examiners read most respectfully includes WAIS-IV for general intellectual functioning, WMS-IV for memory, Trail Making A and B for attention and executive function, Stroop and Wisconsin Card Sorting Test for executive function, Boston Naming Test and verbal fluency for language, Rey Complex Figure for visuoconstruction and visual memory, and the Beck Depression Inventory Second Edition (BDI-II) for the depression overlay that often co-occurs with neurocognitive disorders. The Addenbrooke Cognitive Examination Third Edition (ACE-III) ranges from 0 to 100 with a cutoff of 82 for cognitive impairment and 75 for dementia. It maps onto five domains and is particularly strong for frontotemporal dementia.

Paragraph B: The Four Areas of Mental Functioning

Paragraph B is where most 12.02 files actually win at Step 3. The standard is extreme limitation of one, or marked limitation of two, of these four areas. Understand, remember, or apply information (12.00E1). Interact with others (12.00E2). Concentrate, persist, or maintain pace (12.00E3). Adapt or manage oneself (12.00E4). The four areas come from Section 12.00E and the definitions read identically across every Listing 12 mental disorder.

For neurocognitive claimants, the four B areas track the six cognitive domains in a predictable way. Understand, remember, or apply information is driven by learning and memory plus language. A claimant who can't remember the names of grandchildren, can't follow a two-step instruction, can't recall the address she lived at for 30 years, and can't read a paragraph and answer questions about it has marked or extreme limitation in B1. Interact with others is driven by social cognition plus executive function (because impulse control sits there). A claimant who can't recognize a spouse's emotional state, makes inappropriate sexual comments at the grocery store, says insulting things to a daughter without remembering she said them, and lashes out at home health aides has marked or extreme limitation in B2.

Concentrate, persist, or maintain pace is driven by complex attention and executive function. A claimant who can't sustain attention through a 30-minute conversation, can't follow a recipe she's used for 40 years, can't keep track of multiple ongoing tasks, and falls asleep during simple activities has marked or extreme limitation in B3. Adapt or manage oneself is driven by every domain plus the safety component. A claimant who leaves the stove on, wanders out of the house at night, can't dress for the weather, can't manage her own medication schedule, and can't recognize that a fall requires medical attention has marked or extreme limitation in B4. The B4 area carries the most weight in dementia files because it captures the safety risk that makes work impossible.

The 5-Point Severity Scale in 12.00F

SSA rates each B area on a 5-point scale. None. Mild. Moderate. Marked. Extreme. Verbatim definitions matter because adjudicators apply them as written. None means you can function in the area independently, appropriately, effectively, and on a sustained basis. Mild means slight limitation. Moderate means fair functioning. Marked means seriously limited functioning. Extreme means you are not able to function in the area independently, appropriately, effectively, and on a sustained basis.

Two phrases in those definitions decide most files. "On a sustained basis" means a single moment of clarity doesn't count. A dementia claimant who can answer questions correctly for 5 minutes at a consultative exam but then fades is not sustaining function. "Independently, appropriately, effectively" means doing it alone without prompting. A claimant who can dress only when laid out by a daughter, eat only when reminded by a sticky note, and shower only when accompanied by a home health aide is not functioning independently. Mark every claimant against these phrases in the function report.

Paragraph C: The Two Year Serious and Persistent Path

Paragraph C is the alternative path to Paragraph B for claimants whose neurocognitive disorder has been treated for at least two years and who show only marginal adjustment to daily life. The C language sits in Section 12.00G2 and applies identically across 12.02, 12.03, 12.04, 12.06, and 12.15.

The C criterion has two prongs. C1 requires evidence that you rely on an ongoing basis upon medical treatment, mental health therapy, psychosocial supports, or a highly structured setting to diminish symptoms and signs. C2 requires evidence that despite your diminished symptoms and signs, you have achieved only marginal adjustment. Marginal adjustment means your adaptation to the requirements of daily life is fragile. You have minimal capacity to adapt to changes in your environment or to demands that aren't already part of your daily life. The classic 12.02 Paragraph C profile is a claimant with moderate Alzheimer disease, on donepezil 10 mg plus memantine 20 mg, attending a day program three times a week, living in an assisted living facility, and decompensating whenever the routine changes. A medication switch triggers confusion. A move from one room to another triggers sundowning. A holiday visit from grandchildren triggers a week of agitation. That file wins on Paragraph C.

Highly structured setting under 12.00D2 includes residential treatment, group homes, supervised independent living, day treatment programs, and adult day health programs. An assisted living facility with memory care unit clearly qualifies. So does a private home where a 24-hour live-in caregiver provides supervision, medication management, and behavioral redirection. The chart needs to document the supports, not just say "lives with family."

The Medications and Treatments SSA Expects to See

SSA examiners read medication lists for evidence the diagnosis is being treated. The 2026 standard treatments for major neurocognitive disorders include cholinesterase inhibitors and NMDA receptor antagonists for Alzheimer disease. Donepezil (Aricept) 5 to 10 mg daily for mild to moderate Alzheimer, 23 mg daily for moderate to severe. Rivastigmine (Exelon) oral 1.5 to 6 mg twice daily, or transdermal patch 4.6 to 13.3 mg per 24 hours. Galantamine (Razadyne) 8 to 24 mg daily. Memantine (Namenda) 5 to 20 mg daily for moderate to severe Alzheimer. Combination donepezil-memantine (Namzaric) for patients stabilized on both.

The newer anti-amyloid monoclonal antibodies changed the treatment record SSA sees in 2026. Lecanemab (Leqembi), approved by the FDA in January 2023 with full approval July 2023, is given IV every two weeks for early Alzheimer disease and mild cognitive impairment due to Alzheimer with confirmed amyloid pathology. Donanemab (Kisunla), approved July 2024, is given IV every four weeks for the same indication. Aducanumab (Aduhelm) was withdrawn from the market in early 2024. A claimant receiving lecanemab or donanemab has clear evidence of an Alzheimer diagnosis confirmed by amyloid PET or cerebrospinal fluid biomarkers, because both drugs require that confirmation before payers approve them.

For Parkinson disease with cognitive impairment, the workhorse is carbidopa-levodopa (Sinemet), with adjuncts including ropinirole, pramipexole, rasagiline, and rivastigmine for dementia. For Lewy body dementia, rivastigmine is first-line. Antipsychotics are dangerous in Lewy body and need to be avoided or used with extreme caution. Pimavanserin (Nuplazid) is FDA-approved for Parkinson disease psychosis. For vascular dementia, treatment focuses on cardiovascular risk factors (statins, antiplatelets, blood pressure control) plus cholinesterase inhibitors as adjuncts. For frontotemporal dementia, no disease-modifying treatment exists. SSRIs are used for behavioral symptoms. Trazodone for sleep disturbance and agitation. For traumatic brain injury sequelae, amantadine is used for arousal and attention, methylphenidate for attention and processing speed, and SSRIs for the post-TBI depression and irritability syndrome.

The Imaging That Backs the Diagnosis

SSA reads radiology reports. The 2026 imaging standard for Alzheimer disease confirmation includes MRI showing medial temporal lobe atrophy and hippocampal volume loss, FDG-PET showing temporoparietal hypometabolism, amyloid PET (florbetapir, florbetaben, flutemetamol) showing positive amyloid burden, and tau PET (flortaucipir, Tauvid) showing the neurofibrillary tangle pattern. Cerebrospinal fluid biomarkers, including amyloid beta 42 and tau ratios, also confirm Alzheimer pathology and the Lumipulse G beta-amyloid ratio test received FDA clearance in May 2022. For vascular dementia, MRI shows white matter hyperintensities, lacunar infarcts, and territorial strokes. For frontotemporal dementia, MRI shows frontal and temporal pole atrophy. For Lewy body dementia, dopamine transporter SPECT (DaTscan) shows reduced striatal uptake. For traumatic brain injury, MRI shows microbleeds, diffuse axonal injury patterns, and focal contusions. CT may be normal in mild TBI. Susceptibility weighted imaging picks up microbleeds that other sequences miss.

The Consultative Examination Trap

If the claimant doesn't have a treating neurologist or neuropsychologist, SSA orders a consultative examination. CE psychologists typically administer a short battery: MMSE, a brief executive function screen, and a Beck Depression Inventory. The CE report rarely includes the depth of testing required to map all four B areas with confidence. A claimant whose file rests on a CE alone, without longitudinal neuropsychological testing from a treating provider, is in a weak position. The fix is to request that the CE include a full neuropsychological battery or to obtain that testing privately and submit it to SSA. A neurocognitive disorder file without WMS-IV memory data, executive function data, and language data is missing the evidence required to prove Paragraph A and to score Paragraph B.

Worked Example: Worcester Massachusetts Early-Onset Alzheimer

Patricia is 58, lives in Worcester Massachusetts, and worked as an elementary school teacher for 32 years. Symptoms began at 55 with word-finding difficulties and forgetting student names she had known for years. Her primary care doctor referred her to a neurologist at UMass Memorial. MRI at age 56 showed mild hippocampal atrophy. Neuropsychological testing at age 56 showed WMS-IV Delayed Memory Index of 72, Logical Memory II at the 4th percentile, and Trail Making B time of 180 seconds (severely impaired). Amyloid PET at age 57 was positive. CSF biomarkers showed amyloid beta 42 of 320 pg/mL and elevated phospho-tau. Diagnosis: early-onset Alzheimer disease, probable.

By age 58 Patricia was on donepezil 10 mg, memantine 20 mg, and lecanemab IV every two weeks. She stopped working at age 57 after multiple incidents of getting lost driving to school. Her husband became her primary support. She could not manage her medication schedule without a weekly pillbox prepared by her husband. She could not prepare a meal beyond a sandwich. She wandered outside the house twice in 2026, once at night in a snowstorm. She was found by a neighbor.

The 12.02 analysis. Paragraph A1 satisfied. Significant cognitive decline documented in learning and memory (WMS-IV DMI 72, 3 SD below mean), executive function (Trail Making B at the 1st percentile), and language (Boston Naming Test at the 5th percentile). Three cognitive domains hit, listing only requires one.

Paragraph B analysis. Understand, remember, or apply information: marked. Patricia could not retain new information for more than a few minutes, could not follow multi-step instructions, and could not recall recent autobiographical events. Interact with others: moderate. Social cognition was relatively preserved at this stage. Concentrate, persist, or maintain pace: marked. She could not sustain attention through a conversation and could not complete a task without redirection. Adapt or manage oneself: extreme. She could not manage medications, could not manage her own safety (wandering, getting lost driving), and could not maintain personal hygiene without prompting. Patricia met Listing 12.02 on Paragraph B with two markeds plus one extreme. The file was approved at the initial level with a fully favorable decision.

Patricia's case template: early-onset Alzheimer, biomarker-confirmed diagnosis, full neuropsychological battery showing three cognitive domains hit at 2 SD or worse, current treatment with both cholinesterase inhibitor and NMDA antagonist plus anti-amyloid antibody, documented safety incidents (wandering, driving), and a function report that scored two markeds and one extreme across the four B areas. See the Massachusetts state page for SSDI and SSI numbers.

Worked Example: Orlando Florida Post-TBI Cognitive Disorder

Marcus is 41, lives in Orlando Florida, and worked as a HVAC technician for 15 years. He was hit by a drunk driver on State Road 408 in January 2024. He suffered a severe traumatic brain injury with bilateral frontal contusions, diffuse axonal injury, and subarachnoid hemorrhage. He was in a coma for 6 days at Orlando Health Orlando Regional Medical Center. He spent 8 weeks in inpatient rehabilitation. He was discharged with significant cognitive and behavioral deficits.

Two years later, Marcus had not returned to work. Neuropsychological testing 18 months post-injury showed WAIS-IV Full Scale IQ of 76 (down from a pre-injury estimate of 105 based on academic records), WMS-IV Delayed Memory Index of 68, Trail Making B time of 220 seconds, and severely impaired Stroop interference. The Frontal Assessment Battery scored 9 out of 18. The Iowa Gambling Task showed impaired decision-making. The Neuropsychiatric Inventory showed elevated agitation, disinhibition, and irritability.

Marcus was treated with amantadine 200 mg daily for arousal, methylphenidate 20 mg twice daily for attention, and sertraline 100 mg for post-TBI depression and irritability. He attended a brain injury day program three days a week at the Brain Injury Association of Florida network. He lived with his sister, who managed his finances, medications, and appointments after he wrote $4,200 in checks to telemarketers in a 6-week period.

The 12.02 analysis. Paragraph A1 satisfied. Significant cognitive decline in complex attention (Trail Making B at the 1st percentile), executive function (FAB 9 of 18, impaired Iowa Gambling Task), learning and memory (WMS-IV DMI 68), and social cognition (NPI elevated, multiple incidents of inappropriate behavior).

Paragraph B analysis. Understand, remember, or apply information: marked. Marcus could not retain new technical information, could not follow service manuals he had used for 15 years, and could not learn new HVAC equipment. Interact with others: marked. He had been fired from a brief return-to-work attempt for inappropriate comments to a female coworker, had three documented arguments with his sister in three months, and had two incidents at the day program involving raised voices and a threatened physical altercation. Concentrate, persist, or maintain pace: marked. He could not sustain attention for more than 20 minutes, could not complete a task without redirection, and could not work at a consistent pace. Adapt or manage oneself: marked. He could not manage finances (the telemarketer incident), could not manage medications without his sister, and could not adapt to schedule changes without escalating irritability. Marcus met Listing 12.02 on Paragraph B with four markeds.

His file also met Paragraph C as a backup theory. Two years of documented treatment from January 2024 through January 2026. Ongoing medical treatment (medications and day program). Highly structured setting (living with sister who served as proxy decision-maker, attending day program). Marginal adjustment shown by the telemarketer financial exploitation, the workplace incident on attempted return, and the documented decompensations on routine changes. See the Florida state page for SSDI and SSI numbers.

How To Build the 12.02 File That Wins

The file that wins at Step 3 has six components. First, a confirmed diagnosis from a neurologist or geriatric psychiatrist with the underlying cause identified (Alzheimer, vascular, frontotemporal, Lewy body, Parkinson, TBI, HIV, prion, substance-induced). Second, neuropsychological testing within the last 12 months documenting deficits in at least one of the six cognitive domains at 2 SD or worse. Third, imaging that supports the diagnosis (MRI for atrophy pattern, FDG-PET for hypometabolism, amyloid PET for Alzheimer confirmation, DaTscan for Lewy body). Fourth, a medication list that proves treatment (cholinesterase inhibitors, memantine, anti-amyloid antibodies for Alzheimer, dopaminergic agents for Parkinson, behavioral medications as adjuncts). Fifth, a function report that scores each of the four B areas against the verbatim 12.00E language and the 12.00F severity scale. Sixth, a treating source statement on form HA-1152 from the neurologist or treating psychiatrist that scores each B area as marked or extreme with specific clinical examples drawn from progress notes.

The treating source statement carries the most weight. SSA 20 CFR 404.1520c requires the adjudicator to evaluate the persuasiveness of medical opinions on supportability and consistency. A treating source statement that quotes the 12.00E language, references specific neuropsychological testing scores, and ties them to functional examples from progress notes is the most persuasive evidence in the file. A statement that just checks boxes on a generic form with no narrative is weak. The strongest statements include 2 or 3 paragraphs per B area with specific incidents, dates, and clinical observations.

What To Do If You Lose at the Initial Level

If your initial 12.02 file is denied, the reconsideration step rarely changes the outcome. The ALJ hearing is where neurocognitive cases get fixed. Three moves matter at the hearing level. First, obtain updated neuropsychological testing if the existing testing is more than 12 months old. SSA examiners discount old testing when the diagnosis is progressive. Second, obtain a treating source statement from the neurologist or psychiatrist that explicitly maps each B area to the 12.00E language and the 12.00F severity scale with clinical examples. Third, request a medical expert at the hearing who can review the file and testify to whether the listing is met. The medical expert is appointed by the ALJ and is typically a board-certified neurologist or psychiatrist. A strong neuropsychological battery and a strong treating source statement give the medical expert the foundation to opine that the listing is met.

Massachusetts ALJ hearings are heard at the Boston Office of Hearings Operations and the Lawrence OHO. Average wait time at filing through hearing decision is 14 to 16 months in 2026. Florida ALJ hearings are heard at the Orlando, Miami, Tampa, Fort Lauderdale, and Jacksonville OHOs. Average wait time is 12 to 14 months. The hearing-level allowance rate for mental disorder cases including 12.02 is 47 to 52 percent depending on hearing office. The combined approval rate across initial, reconsideration, and hearing for neurocognitive disorders is 65 to 70 percent for properly developed files.

Related deep dives that cross-reference 12.02: Listing 12.04 depressive and bipolar disorders for the depression overlay that often coexists with neurocognitive disorders, Listing 12.15 PTSD and trauma related disorders for the post-TBI PTSD overlay, and Listing 12.06 anxiety and OCD for the anxiety overlay that often co-occurs with early-stage dementia.

Frequently Asked Questions